The new "Skyline" clinical trial, which has just opened as part of the RHU CASSIOPEIA Future Investment Program at Institut Curie, the 1st European center for breast cancer management, has a double objective: to evaluate the effectiveness of a new combination of two immunotherapies in combination with chemotherapy in women with triple-negative breast cancer and to better visualize the cancer and its possible metastases thanks to innovative imaging used for the first time in France.